Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Director | September 21, 2023 | October 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CNS Pharmaceuticals, Inc.
Report date September 21, 2023 · Filed October 12, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2033-09-22 | Direct | 45,428 |
Reported balance
After 2023-09-21 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-09-21 · Grant · Acquired 39,475 · Balance 45,428 F2: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.
F2: The stock options were issued in connection with the reporting person's Board of Director services to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2023 Filed Sep 25, 2023 22:20 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 68,961 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-006676 · ownership.xml · derivative · entry 1 Andraczke Andrzej · CIK 0001792732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,914 Underlying: Common Stock · 68,961 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| September 21, 2023 Filed Oct 12, 2023 22:00 UTC Amendment | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 39,475 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-007106 · ownership.xml · derivative · entry 1 Andraczke Andrzej · CIK 0001792732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,428 Underlying: Common Stock · 39,475 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 32,000 | Not disclosed Strike: $1.80 | Not disclosed |
DisclosureSEC source: 0001683168-21-002999 · ownership.xml · derivative · entry 1 Andraczke Andrzej · CIK 0001792732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,559 Underlying: Common Stock · 32,000 shares Expires 2031-07-15 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date hereof or the date of the 2022 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:22 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 46,559 | Not disclosed Strike: $2.47 | Not disclosed |
DisclosureSEC source: 0001683168-20-001965 · ownership.xml · derivative · entry 1 Andraczke Andrzej · CIK 0001792732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,559 Underlying: Common Stock · 46,559 shares Expires 2030-06-12 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the issuance date or the date of the 2021 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.